Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)‘s stock had its “hold” rating reissued by Jefferies Group LLC in a report issued on Friday. They currently have a $1.75 target price on the biopharmaceutical company’s stock, down from their previous target price of $2.25. Jefferies Group LLC’s price objective would indicate a potential upside of 37.80% from the company’s current price.

ANTH has been the subject of several other research reports. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. ValuEngine lowered shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $10.11.

Anthera Pharmaceuticals (ANTH) opened at 1.27 on Friday. The company’s 50 day moving average is $1.50 and its 200-day moving average is $1.13. The stock’s market cap is $12.80 million. Anthera Pharmaceuticals has a 52-week low of $0.30 and a 52-week high of $3.55.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.09) by $1.12. On average, equities analysts anticipate that Anthera Pharmaceuticals will post ($3.88) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Jefferies Group LLC Reiterates Hold Rating for Anthera Pharmaceuticals, Inc. (ANTH)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/13/jefferies-group-llc-reiterates-hold-rating-for-anthera-pharmaceuticals-inc-anth.html.

Several large investors have recently added to or reduced their stakes in ANTH. Goldman Sachs Group Inc. raised its stake in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the last quarter. UBS Group AG raised its stake in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the last quarter. Finally, Sabby Management LLC raised its stake in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.